These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate. Dandan M; Han J; Mann S; Kim R; Li K; Mohammed H; Chuang JC; Zhu K; Billin AN; Huss RS; Chung C; Myers RP; Hellerstein M J Lipid Res; 2023 Mar; 64(3):100339. PubMed ID: 36737040 [TBL] [Abstract][Full Text] [Related]
4. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model. Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562 [TBL] [Abstract][Full Text] [Related]
5. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114 [No Abstract] [Full Text] [Related]
6. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents. Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582 [TBL] [Abstract][Full Text] [Related]
7. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems. Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482 [TBL] [Abstract][Full Text] [Related]
9. A new mechanism of thyroid hormone receptor β agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles. Sun K; Zhu NL; Huang SL; Qu H; Gu YP; Qin L; Liu J; Leng Y Acta Pharmacol Sin; 2024 Oct; 45(10):2134-2148. PubMed ID: 38789494 [TBL] [Abstract][Full Text] [Related]
10. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis. Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961 [TBL] [Abstract][Full Text] [Related]
11. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis. Choi YJ; Johnson JD; Lee JJ; Song J; Matthews M; Hellerstein MK; McWherter CA Am J Physiol Gastrointest Liver Physiol; 2024 Feb; 326(2):G120-G132. PubMed ID: 38014444 [TBL] [Abstract][Full Text] [Related]
12. Capparis spinosa improves non-alcoholic steatohepatitis through down-regulating SREBP-1c and a PPARα-independent pathway in high-fat diet-fed rats. Akbari R; Yaghooti H; Jalali MT; Khorsandi LS; Mohammadtaghvaei N BMC Res Notes; 2022 Oct; 15(1):315. PubMed ID: 36192786 [TBL] [Abstract][Full Text] [Related]
18. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients. Lawitz EJ; Li KW; Nyangau E; Field TJ; Chuang JC; Billin A; Wang L; Wang Y; Huss RS; Chung C; Subramanian GM; Myers RP; Hellerstein MK J Lipid Res; 2022 Sep; 63(9):100250. PubMed ID: 35835205 [TBL] [Abstract][Full Text] [Related]
19. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice. Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823 [TBL] [Abstract][Full Text] [Related]
20. Nicotinate-curcumin improves NASH by inhibiting the AKR1B10/ACCα-mediated triglyceride synthesis. Lin XL; Zeng YL; Ning J; Cao Z; Bu LL; Liao WJ; Zhang ZM; Zhao TJ; Fu RG; Yang XF; Gong YZ; Lin LM; Cao DL; Zhang CP; Liao DF; Li YM; Zeng JG Lipids Health Dis; 2024 Jun; 23(1):201. PubMed ID: 38937844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]